AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25468397 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication skills training for primary care doctors
Number of subjects: 379
Study 25468397 — intervention group
Group type: COMPARATOR
Intervention: Usual care controls
Number of subjects: 379
Study 22874533 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast Quality Index (BQI) score
Number of subjects: 4332
Study 21036454 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone CPR (guided intervention)
Number of subjects: 110
Study 21036454 — intervention group
Group type: COMPARATOR
Intervention: No phone CPR (non-guided intervention)
Number of subjects: 110
Study 18311814 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpharmacologic intervention to reduce pain
Number of subjects: 10
Study 16781381 — intervention group
Group type: COMPARATOR
Intervention: Left atrial ablation
Number of subjects: 80
Study 16781381 — intervention group
Group type: EXPERIMENTAL
Intervention: Biatrial ablation
Number of subjects: 80
Study 12703850 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (3 times a week for 9 weeks)
Number of subjects: 23
Study 12703850 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 23
Study 12703850 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 11)
Number of subjects: 23
Study 10896016 — intervention group
Group type: EXPERIMENTAL
Intervention: Scapula manually stabilized
Number of subjects: 50
Study 10896016 — intervention group
Group type: COMPARATOR
Intervention: Scapula unstabilized
Number of subjects: 50
Study 9282768 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy (LA)
Number of subjects: 210
Study 9282768 — intervention group
Group type: COMPARATOR
Intervention: Open appendectomy (OA)
Number of subjects: 210
Study 8419602 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized racemic epinephrine, 0.1 ml/kg
Number of subjects: 24
Study 8419602 — intervention group
Group type: COMPARATOR
Intervention: Nebulized salbutamol, 0.03 ml/kg
Number of subjects: 24
Study 3523368 — intervention group
Group type: EXPERIMENTAL
Intervention: tixocortol pivalate-neomycin
Number of subjects: 60
Study 3523368 — intervention group
Group type: COMPARATOR
Intervention: neomycin
Number of subjects: 60
Study 31311595 — intervention group
Group type: EXPERIMENTAL
Intervention: Real multimodal group (RMG) - multimodal physical exercises in a real environment, 2 times per week for 60 minutes per session for 15 weeks
Number of subjects: 36
Study 31311595 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual multimodal group (VMG) - multimodal physical exercises in a virtual environment, 2 times per week for 60 minutes per session for 15 weeks
Number of subjects: 36
Study 31311595 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined multimodal group (CMG) - one session in a real environment and one session in a virtual environment per week for 15 weeks
Number of subjects: 36
Study 29630789 — intervention group
Group type: EXPERIMENTAL
Intervention: Anhydrous 0.454% SnF2 dentifrice containing 5% sodium tripolyphosphate (STP)
Number of subjects: 214
Study 29630789 — intervention group
Group type: COMPARATOR
Intervention: Standard fluoride dentifrice (0.76% fluoride as sodium monofluorophosphate [SMFP])
Number of subjects: 214
Study 27005290 — intervention group
Group type: EXPERIMENTAL
Intervention: Local wound infiltration plus TAP block
Number of subjects: 48
Study 27005290 — intervention group
Group type: COMPARATOR
Intervention: Local wound infiltration
Number of subjects: 48
Study 25257687 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led Diabetes Management Education Program (DMEP)
Number of subjects: 8
Study 25257687 — intervention group
Group type: COMPARATOR
Intervention: Standard pharmacy care (control group)
Number of subjects: 8
Study 23342780 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalp-acupoint catgut embedding, once a week for 4 weeks
Number of subjects: 64
Study 23342780 — intervention group
Group type: COMPARATOR
Intervention: Routine acupuncture, 3 times a week for 4 weeks
Number of subjects: 64
Study 20157180 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocrelizumab 200 mg/m2 (n=15)
Number of subjects: 47
Study 20157180 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocrelizumab 375 mg/m2 (n=16)
Number of subjects: 47
Study 20157180 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocrelizumab 375 mg/m2 first dose, then 750 mg/m2 (n=16)
Number of subjects: 47
Study 20157180 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocrelizumab (all cohorts)
Number of subjects: 47
Study 18413070 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted hatching (AH) in frozen-thawed embryo transfer cycles
Number of subjects: 960
Study 18413070 — intervention group
Group type: COMPARATOR
Intervention: Control group (no assisted hatching) in frozen-thawed embryo transfer cycles
Number of subjects: 960
Study 18413070 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted hatching (AH) in fresh embryo transfer cycles
Number of subjects: 960
Study 18413070 — intervention group
Group type: COMPARATOR
Intervention: Control group (no assisted hatching) in fresh embryo transfer cycles
Number of subjects: 960
Study 16006914 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg trospium chloride twice daily
Number of subjects: 658
Study 16006914 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 658
Study 11952288 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracutaneous injections of 100 units of Botulinum toxin A (BTXA) on the more severely affected hand
Number of subjects: 8
Study 11952288 — intervention group
Group type: COMPARATOR
Intervention: Topical corticosteroids
Number of subjects: 8
Study 10631405 — intervention group
Group type: EXPERIMENTAL
Intervention: Perennial allergic rhinitis
Number of subjects: 34
Study 10631405 — intervention group
Group type: EXPERIMENTAL
Intervention: Perennial nonallergic rhinitis
Number of subjects: 34
Study 10631405 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal subjects)
Number of subjects: 34
Study 8636336 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human GH at 0.33 IU/m(2)-day
Number of subjects: 46
Study 8636336 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human GH at 0.66 IU/m(2)-day
Number of subjects: 46
Study 8636336 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human GH at 1.0 IU/m(2)-day
Number of subjects: 46
Study 8636336 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human GH at 2.0 IU/m(2)-day
Number of subjects: 46
Study 8636336 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human GH at 3.0 IU/m(2)-day
Number of subjects: 46
Study 8636336 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human GH (various doses)
Number of subjects: 46
Study 8636336 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human GH (optimal dose)
Number of subjects: 46
Study 1355765 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethindrone
Number of subjects: 72
Study 1355765 — intervention group
Group type: COMPARATOR
Intervention: Levonorgestrel
Number of subjects: 72
Study 6386488 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 0.2 mgs
Number of subjects: 6
Study 6386488 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine 2 mgs
Number of subjects: 6
Study 30636111 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet (LF)
Number of subjects: 246
Study 30636111 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MED)
Number of subjects: 246
Study 30636111 — intervention group
Group type: COMPARATOR
Intervention: Metabolic syndrome (MetS) women
Number of subjects: 246
Study 30636111 — intervention group
Group type: COMPARATOR
Intervention: Metabolic syndrome (MetS) men
Number of subjects: 246
Study 30111472 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine treatment
Number of subjects: 120
Study 30111472 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment
Number of subjects: 120
Study 27285946 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanently implantable wireless pulmonary artery pressure monitoring system
Number of subjects: 0
Study 24614759 — intervention group
Group type: EXPERIMENTAL
Intervention: F-genotype attenuated mumps vaccine A (3.5 ± 0.25 logCCID50)
Number of subjects: 300
Study 24614759 — intervention group
Group type: EXPERIMENTAL
Intervention: F-genotype attenuated mumps vaccine B (4.25 ± 0.25 logCCID50)
Number of subjects: 300
Study 24614759 — intervention group
Group type: EXPERIMENTAL
Intervention: F-genotype attenuated mumps vaccine C (5.0 ± 0.25 logCCID50)
Number of subjects: 300
Study 24614759 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 300
Study 24614759 — intervention group
Group type: COMPARATOR
Intervention: Positive control (licensed A-genotype vaccine S79 strain)
Number of subjects: 300
Study 22327773 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotton gauze dressing removed 48 hours after surgery
Number of subjects: 230
Study 22327773 — intervention group
Group type: COMPARATOR
Intervention: Cotton gauze dressing kept on for 7-8 days until removal of skin sutures (Control)
Number of subjects: 230
Study 20216563 — intervention group
Group type: EXPERIMENTAL
Intervention: Food plus micronutrient capsule (MN) containing 15 mg zinc/day
Number of subjects: 81
Study 20216563 — intervention group
Group type: COMPARATOR
Intervention: Food supplement
Number of subjects: 81
Study 18381791 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant (250 mg intramuscularly for 12 months)
Number of subjects: 20
Study 18381791 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 16011383 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interview
Number of subjects: 195
Study 16011383 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction of logistical barriers to attendance
Number of subjects: 195
Study 16011383 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentive
Number of subjects: 195
Study 16011383 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 195
Study 12407863 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 0
Study 12407863 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 0
Study 12407863 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban and Integrilin
Number of subjects: 0
Study 12407863 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed treatment scheme including clopidogrel and abciximab
Number of subjects: 0
Study 10597334 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg)
Number of subjects: 0
Study 10597334 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (retreatment)
Number of subjects: 0
Study 7488808 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy-dense porridge liquefied with amylase-rich flour (ARF)
Number of subjects: 66
Study 7488808 — intervention group
Group type: COMPARATOR
Intervention: Thick unaltered porridge (Control Group 2)
Number of subjects: 66
Study 7488808 — intervention group
Group type: COMPARATOR
Intervention: Porridge diluted with water (Control Group 3)
Number of subjects: 66
Study 7488808 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy-dense porridge liquefied with ARF
Number of subjects: 66
Study 1823527 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 8
Study 1823527 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 7387805 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Number of subjects: 0
Study 7387805 — intervention group
Group type: COMPARATOR
Intervention: Atropine
Number of subjects: 0
Study 7387805 — intervention group
Group type: COMPARATOR
Intervention: Hyoscine
Number of subjects: 0
Study 29512468 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (systolic BP target of <120 mmHg)
Number of subjects: 1562
Study 29512468 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (systolic BP target of <120 mmHg) with low baseline SBP (<150 mmHg)
Number of subjects: 1562
Study 29512468 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (systolic BP target of <140 mmHg)
Number of subjects: 1562
Study 29042830 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg A-GPC
Number of subjects: 48
Study 29042830 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg A-GPC
Number of subjects: 48
Study 29042830 — intervention group
Group type: COMPARATOR
Intervention: 200 mg Caffeine
Number of subjects: 48
Study 29042830 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 24986062 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 5145
Study 24986062 — intervention group
Group type: COMPARATOR
Intervention: Diabetes support and education (DSE)
Number of subjects: 5145
Study 24492985 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil (OM)/Amlodipine besylate (AM)/Hydrochlorothiazide (HCTZ) 40/10/25 mg
Number of subjects: 40
Study 22806822 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion 100-150 mg/day (100 mg/day for <30 kg and 150 mg/day for >30 kg)
Number of subjects: 44
Study 22806822 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate 20-30 mg/day
Number of subjects: 44
Study 22806822 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 44
Study 22806822 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate
Number of subjects: 44
Study 20506064 — intervention group
Group type: EXPERIMENTAL
Intervention: Probe-based confocal laser endomicroscopy (pCLE)
Number of subjects: 68
Study 17359606 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care mental health workers
Number of subjects: 368
Study 17359606 — intervention group
Group type: COMPARATOR
Intervention: Control practices
Number of subjects: 368
Study 15734768 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete SigmaSTR (>=70%) and MB grade 2/3
Number of subjects: 456
Study 15734768 — intervention group
Group type: EXPERIMENTAL
Intervention: Incomplete SigmaSTR (<70%) and reduced MB (grade 0/1)
Number of subjects: 456
Study 15734768 — intervention group
Group type: EXPERIMENTAL
Intervention: Discordant MB and SigmaSTR
Number of subjects: 456
Study 15734768 — intervention group
Group type: EXPERIMENTAL
Intervention: SigmaSTR
Number of subjects: 456
Study 15734768 — intervention group
Group type: EXPERIMENTAL
Intervention: MB
Number of subjects: 456
Study 11989995 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 45
Study 11989995 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 45
Study 9783884 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide (NAM)
Number of subjects: 19
Study 9783884 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbogen
Number of subjects: 19
Study 9783884 — intervention group
Group type: COMPARATOR
Intervention: Control (no flow modulator)
Number of subjects: 19
Study 7863824 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with previous femur shaft fracture
Number of subjects: 29
Study 7863824 — intervention group
Group type: COMPARATOR
Intervention: Normal men (control group)
Number of subjects: 29
Study 2648763 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rehydration solution with sodium concentration of 35 mmol/l and dextrose of 200 mmol/l
Number of subjects: 269
Study 2648763 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rehydration solution with sodium concentration of 50 mmol/l and dextrose of 111 mmol/l
Number of subjects: 269
Study 2648763 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rehydration solution with sodium concentration of 90 mmol/l and dextrose of 110 mmol/l
Number of subjects: 269
Study 29394109 — intervention group
Group type: EXPERIMENTAL
Intervention: MobileKids Monster Manor (MKMM)
Number of subjects: 37
Study 29394109 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 37
Study 29394109 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower socioeconomic status environment
Number of subjects: 37
Study 27807039 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA24 dietary recall system
Number of subjects: 81
Study 27807039 — intervention group
Group type: COMPARATOR
Intervention: Interviewer-administered Automated Multiple-Pass Method (AMPM) recall
Number of subjects: 81
Study 25633661 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based diabetes dashboard management tool
Number of subjects: 199
Study 24640436 — intervention group
Group type: COMPARATOR
Intervention: OptiBond Solo Plus/Nexus Third Generation (NX3)
Number of subjects: 36
Study 24640436 — intervention group
Group type: EXPERIMENTAL
Intervention: XP Bond/SureFil SDR Flow (SDR)
Number of subjects: 36
Study 24640436 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertise Flow (VF)
Number of subjects: 36
Study 20619448 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management with telemonitoring (n=263)
Number of subjects: 527
Study 20619448 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control) (n=264)
Number of subjects: 527
Study 18788030 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with schizophrenia
Number of subjects: 12
Study 18788030 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 12
Study 16914781 — intervention group
Group type: EXPERIMENTAL
Intervention: High-pressure suction drainage (600 mm Hg)
Number of subjects: 60
Study 16914781 — intervention group
Group type: COMPARATOR
Intervention: Low-pressure suction drainage (350 mm Hg)
Number of subjects: 60
Study 16914781 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 12506170 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil (FU) alone
Number of subjects: 280
Study 12506170 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil plus cisplatin (FP)
Number of subjects: 280
Study 12506170 — intervention group
Group type: EXPERIMENTAL
Intervention: Uracil and tegafur plus mitomycin (UFTM)
Number of subjects: 280
Study 10948025 — intervention group
Group type: EXPERIMENTAL
Intervention: Homoeopathy (30c preparation of principal inhalant allergen)
Number of subjects: 51
Study 10948025 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 10948025 — intervention group
Group type: EXPERIMENTAL
Intervention: Homoeopathy (combined with previous trials)
Number of subjects: 51
Study 8655662 — intervention group
Group type: EXPERIMENTAL
Intervention: High feedback
Number of subjects: 211
Study 8655662 — intervention group
Group type: COMPARATOR
Intervention: Low feedback
Number of subjects: 211
Study 1514295 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sealant for bronchial stump occlusions
Number of subjects: 190
Study 1514295 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sealant for gastrointestinal operations
Number of subjects: 190
Study 1514295 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sealant for emergency abdominal operations
Number of subjects: 190
Study 1514295 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sealant for elective surgery
Number of subjects: 190
Study 1514295 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sealant for pancreatic duct occlusion after Whipple's operation
Number of subjects: 190
Study 1514295 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sealing for prevention of postoperative lymph fistulae
Number of subjects: 190
Study 1514295 — intervention group
Group type: EXPERIMENTAL
Intervention: Instillation of fibrin for existing lymph fistulae
Number of subjects: 190
Study 6337698 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemoendocrine regimen followed by postoperative radiotherapy
Number of subjects: 184
Study 6337698 — intervention group
Group type: COMPARATOR
Intervention: Preoperative chemoendocrine regimen without postoperative radiotherapy
Number of subjects: 184
Study 30514651 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental incarceration
Number of subjects: 3972
Study 30514651 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal incarceration
Number of subjects: 3972
Study 30514651 — intervention group
Group type: EXPERIMENTAL
Intervention: Paternal incarceration
Number of subjects: 3972
Study 30514651 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental incarceration before age 10
Number of subjects: 3972
Study 29458927 — intervention group
Group type: EXPERIMENTAL
Intervention: Olfactory mental imagery (test group)
Number of subjects: 80
Study 29458927 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 80
Study 26819104 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral tube feeding in addition to standard care
Number of subjects: 0
Study 26819104 — intervention group
Group type: COMPARATOR
Intervention: Standard care with intravenous rehydration
Number of subjects: 0
Study 24516621 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet (D) treatment
Number of subjects: 68
Study 24516621 — intervention group
Group type: COMPARATOR
Intervention: Exercise (E) treatment
Number of subjects: 68
Study 24516621 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 68
Study 21471562 — intervention group
Group type: EXPERIMENTAL
Intervention: ChemoEd intervention (DVD, question-prompt list, self-care information, education consultation ≥24 h before first treatment, telephone follow-up 48 h after first treatment, face-to-face review immediately before second treatment)
Number of subjects: 192
Study 21471562 — intervention group
Group type: EXPERIMENTAL
Intervention: ChemoEd intervention
Number of subjects: 192
Study 20217071 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 79
Study 17693650 — intervention group
Group type: COMPARATOR
Intervention: VAD-doxil
Number of subjects: 232
Study 17693650 — intervention group
Group type: EXPERIMENTAL
Intervention: TVAD-doxil
Number of subjects: 232
Study 16183965 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein and carbohydrate (PC) supplementation after resistance exercise
Number of subjects: 6
Study 16183965 — intervention group
Group type: COMPARATOR
Intervention: Placebo (NON)
Number of subjects: 6
Study 12137177 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit learning group
Number of subjects: 0
Study 12137177 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit learning group
Number of subjects: 0
Study 12137177 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 0